🔗 Permalink

Inventor profile of:

Shyra Gardai

City:

Bothell, Washington

Country:

United States

Published Applications:

Last publication date:

2025-02-27

Top Assignees for applications by Shyra Gardai

The entities that hold a legal rights for patent applications filed by inventor Gardai Shyra:

SEAGEN INC. 8 Bothell, WA United States
Seattle Genetics, Inc. 5 Bothell, WA United States
GENMAB A/S 2 Copenhagen V, Denmark
MSD INTERNATIONAL GMBH 1 Luzerne, Switzerland
MSD International GMBH 1 Lucerne, Switzerland
MSD International GmbH 1 Luzern 6, Switzerland
GENMAB A/S 1 Valby, Denmark

Recent patent applications by Gardai Shyra

Shyra Gardai from Bothell, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-02-27

US20250066507A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

#2 | 2024-05-23

US20240166757A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH NONFUCOSYLATED ANTI-CD70 ANTIBODIES

#3 | 2024-04-11

US20240117400A1

Chemistry; metallurgy

T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME

#4 | 2024-03-07

US20240075135A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES

#5 | 2024-03-07

US20240075134A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY

#6 | 2023-09-07

US20230279133A1

Chemistry; metallurgy

MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES

#7 | 2023-06-29

US20230203175A1

Chemistry; metallurgy

Anti-CD40 Antibody Combination Treatment for Cancer

#8 | 2023-06-29

US20230201344A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY

#9 | 2023-06-29

US20230201343A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES

#10 | 2023-04-20

US20230117205A1

Human necessities

B7-H4 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER

#11 | 2023-02-16

US20230050440A1

Chemistry; metallurgy

Anti-TIGIT Antibodies

#12 | 2023-01-26

US20230027495A1

Human necessities

METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

#13 | 2022-08-25

US20220265822A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY

#14 | 2022-08-11

US20220249662A1

Human necessities

DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES

#15 | 2022-05-05

US20220135674A1

Chemistry; metallurgy

CD47 antibodies and uses thereof for treating cancer

#16 | 2022-03-24

US20220088191A1

Human necessities

METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

#17 | 2021-07-22

US20210221897A1

Chemistry; metallurgy

Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies

#18 | 2021-04-15

US20210107980A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE

#19 | 2020-07-30

US20200239585A1

Chemistry; metallurgy

MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES

#20 | 2020-05-14

US20200149082A1

Chemistry; metallurgy

T cells with reduced surface fucosylation and methods of making and using the same

#21 | 2020-02-27

US20200062859A1

Chemistry; metallurgy

Anti-TIGIT antibodies

#22 | 2019-06-20

US20190185561A1

Chemistry; metallurgy

CD47 antibodies and uses thereof for treating cancer

#23 | 2018-12-13

US20180353524A1

Human necessities

CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT INHIBITOR

#24 | 2017-11-23

US20170333556A1

Human necessities

Dosage and administration of non-fucosylated anti-CD40 antibodies

#25 | 2017-05-18

US20170137528A1

Chemistry; metallurgy

Dosage and administration of non-fucosylated anti-CD40 antibodies

InventorID:

1877535 ⎘